Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCMP
1376
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $8.51M | 0.01% |
810,600
-300,800
| -27% | -$3.07M |
|
|
EMKR
1377
DELISTED
Emcore Corp
EMKR
| $8.51M | 0.01% |
79,920
-23,512
| -23% | -$2.35M |
|
|
MCBC
1378
DELISTED
Macatawa Bank Corp
MCBC
| $8.49M | 0.01% |
889,700
+600
| +0.1% | +$5.75K |
|
|
SUPV
1379
Grupo Supervielle
SUPV
$707M
| $8.48M | 0.01% |
469,290
+322,538
| +220% | +$5.54M |
|
1380
Azenta
AZTA
$1.45B
| $8.48M | 0.01% |
391,057
+215,400
| +123% | +$5.46M |
|
|
TEP
1381
DELISTED
Tallgrass Energy Partners, LP
TEP
| $8.48M | 0.01% |
169,300
-101,300
| -37% | -$5.05M |
|
1382
Whirlpool
WHR
$2.7B
| $8.46M | 0.01% |
+44,157
| New | +$8.08M |
|
1383
Carlyle Group
CG
$17.7B
| $8.44M | 0.01% |
427,400
+201,810
| +89% | +$3.56M |
|
|
SREV
1384
DELISTED
ServiceSource International, Inc.
SREV
| $8.42M | 0.01% |
2,170,646
-24,000
| -1% | -$86.2K |
|
|
NEWR
1385
DELISTED
New Relic, Inc.
NEWR
| $8.42M | 0.01% |
195,800
+178,700
| +1,045% | +$7.44M |
|
|
GWPH
1386
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.42M | 0.01% |
84,000
-6,200
| -7% | -$667K |
|
1387
Generac Holdings
GNRC
$12.9B
| $8.41M | 0.01% |
+232,800
| New | +$8.32M |
|
1388
NVE Corp
NVEC
$580M
| $8.36M | 0.01% |
108,600
+700
| +0.6% | +$55.9K |
|
1389
Flowserve
FLS
$10.3B
| $8.36M | 0.01% |
+180,000
| New | +$8.68M |
|
|
EEQ
1390
DELISTED
Enbridge Energy Management Llc
EEQ
| $8.35M | 0.01% |
624,320
+94,359
| +18% | +$1.37M |
|
|
CARO
1391
DELISTED
Carolina Financial Corp.
CARO
| $8.35M | 0.01% |
258,300
+67,200
| +35% | +$2.06M |
|
|
CIO
1392
DELISTED
City Office REIT
CIO
| $8.35M | 0.01% |
657,200
+45,300
| +7% | +$564K |
|
1393
Fortis
FTS
$28.9B
| $8.33M | 0.01% |
237,000
+135,000
| +132% | +$4.49M |
|
1394
Trustmark
TRMK
$2.81B
| $8.33M | 0.01% |
258,904
-105,000
| -29% | -$3.37M |
|
1395
National Presto Industries
NPK
$1B
| $8.32M | 0.01% |
75,300
+7,100
| +10% | +$750K |
|
1396
First Financial Bancorp
FFBC
$3.61B
| $8.32M | 0.01% |
300,300
-15,500
| -5% | -$417K |
|
|
DSPG
1397
DELISTED
DSP Group Inc
DSPG
| $8.31M | 0.01% |
716,494
+56,494
| +9% | +$685K |
|
|
QEP
1398
DELISTED
QEP RESOURCES, INC.
QEP
| $8.3M | 0.01% |
822,100
-358,600
| -30% | -$3.89M |
|
|
ARRY
1399
DELISTED
Array Biopharma Inc
ARRY
| $8.29M | 0.01% |
+990,441
| New | +$8.1M |
|
1400
Quantum Corp
QMCO
$1.06B
| $8.28M | 0.01% |
52,982
+2,818
| +6% | +$438K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.